In mantle cell lymphoma (MCL), SEs regulate genes related to cell survival through BRD4, such as B cell receptor (BCR) signaling and IKZF-MYC axis, and the inhibition of BRD4 may overcome MCL resistance to ibrutinib (BCR pathway inhibitor) or lenalidomide (IKZF inhibitor) [140]. The gene discussed is MYC; the disease is mantle cell lymphoma.